Abstract 2109P
Background
Vitamin deficiencies and supplement intake is discussed controversially in oncology. Therefore, we aimed to investigate vitamin D, A and E levels and their correlation with clinical characteristics and symptomatic burden in a large pan-cancer cohort.
Methods
25-hydroxy-vitamin D, vitamin A, and vitamin E levels were measured at treatment start in patients receiving palliative cancer treatment at the Medical University of Vienna (MUV) included in the “Biobanking Program for Personalized Immunotherapy” between May 2019 and March 2022. Measurements were performed using a chemiluminescence immunoassay (vitamin D) and high performance liquid chromatography (vitamin A, vitamin E) established at the Department of Laboratory Medicine (MUV). Cut off values defining the normal range were predefined as follows: vitamin D (75-250nmol/L), vitamin A (1.05-2.45μmol/L), vitamin E (12.0-42.0μmol/L). Symptom burden was assessed using the EORTC quality of life questionnaire QLQC-30 and its subscore assessing fatigue.
Results
Vitamin D, A, and E levels were measured in a total of 231 patients (92 females, 139 males, median age: 64 years [range: 23-89]). Median vitamin levels were as follows: vitamin D 66.9nmol/l (range: 10.4-186.0nmol/l), vitamin A 1.64μmol/l (range: 0.29-4.22μmol/l), and vitamin E 35.8μmol/l (range: 20.2-76.8μmol/l). Patients presented with vitamin D deficiencies in 138/231 (59.7%) and vitamin A deficiencies in 34/231 cases (14.7%). No vitamin E deficiencies were detected, however, 25/231 patients (24.2%) presented with vitamin E levels above normal. Vitamin A levels were increased in 26/231 patients (11.3%), while vitamin D levels above the upper limit of normal in 1/231 patient (0.4%). No correlations between vitamin levels and clinical characteristics at sample collection such as sex, age, tumor origin, symptom burden or fatigue were observed (p>0.05). Additionally, no correlation between vitamin levels and overall survival could be detected (p>0.05).
Conclusions
Even though vitamin deficiencies are common in patients with cancer, no influences of vitamin levels on symptom burden, fatigue or survival could be detected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association.
Disclosure
A.M. Starzer: Financial Interests, Personal, Invited Speaker, Lecture honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant, Industry partner of institutional Christian Doppler Laboratory: Roche; Non-Financial Interests, Member, National Oncology Society: OeGHO; Non-Financial Interests, Member, Oncology society of USA: ASCO; Other, Travel support for conference participation: MSD, Lilly. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer-Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06